Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention
The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases. The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention. A total of 1724 p...
Saved in:
Published in | Annals of medicine (Helsinki) Vol. 54; no. 1; pp. 1667 - 1677 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Taylor & Francis
31.12.2022
Taylor & Francis Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.
The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization.
During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001).
SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention.
KEY MESSAGES
The SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.
Higher SIRI is associated with a more severe disease status.
The SIRI could increase the prognostic value of the GRACE risk score. |
---|---|
AbstractList | The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.
The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization.
During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001).
SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention.
KEY MESSAGES
The SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.
Higher SIRI is associated with a more severe disease status.
The SIRI could increase the prognostic value of the GRACE risk score. The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.BACKGROUNDThe systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.OBJECTIVESThe aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization.METHODSA total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization.During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001).RESULTSDuring a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001).SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGESThe SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.Higher SIRI is associated with a more severe disease status.The SIRI could increase the prognostic value of the GRACE risk score.CONCLUSIONSIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGESThe SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.Higher SIRI is associated with a more severe disease status.The SIRI could increase the prognostic value of the GRACE risk score. The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases. The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention. A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization. During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034-1.229 = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, = .040; net reclassification improvement: 0.175, = .020; likelihood ratio test: < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE ( < .001). SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGESThe SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.Higher SIRI is associated with a more severe disease status.The SIRI could increase the prognostic value of the GRACE risk score. Background The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.Objectives The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.Methods A total of 1724 patients with ACS enrolled from June 2016 to November 2017 at a single centre were included in this study, and SIRI was calculated for each patient. The primary endpoint was the composite of major adverse cardiovascular events (MACE), including overall death, non-fatal myocardial infarction, non-fatal stroke, and unplanned repeat revascularization.Results During a median follow-up of 927 days, 355 patients had MACE. Multivariate Cox analysis showed that SIRI was significantly associated with MACE (hazard ratio: 1.127, 95% confidence interval: 1.034–1.229 p = .007). The results were consistent in multiple sensitivity analyses. The addition of SIRI had an incremental effect on the predictive ability of the Global Registry of Acute Coronary Events risk score for MACE (integrated discrimination improvement: 0.007, p = .040; net reclassification improvement: 0.175, p = .020; likelihood ratio test: p < .001). The restricted cubic spline showed a monotonic increase with a greater SIRI value for MACE (p < .001).Conclusion SIRI was an independent risk factor for MACE and provided incremental prognostic information in patients with ACS undergoing percutaneous coronary intervention. KEY MESSAGESThe SIRI is a strong and independent risk factor for adverse outcomes in patients with ACS undergoing percutaneous coronary intervention.Higher SIRI is associated with a more severe disease status.The SIRI could increase the prognostic value of the GRACE risk score. |
Author | Wang, Zhijian Ma, Xiaoteng Gao, Fei Liu, Yuyang Han, Kangning Li, Yueping Yang, Lixia Shi, Dongmei Zhou, Yujie |
Author_xml | – sequence: 1 givenname: Kangning surname: Han fullname: Han, Kangning organization: Beijing Institute of Heart, Lung and Blood Vessel Disease – sequence: 2 givenname: Dongmei surname: Shi fullname: Shi, Dongmei organization: Beijing Institute of Heart, Lung and Blood Vessel Disease – sequence: 3 givenname: Lixia surname: Yang fullname: Yang, Lixia organization: Beijing Institute of Heart, Lung and Blood Vessel Disease – sequence: 4 givenname: Zhijian surname: Wang fullname: Wang, Zhijian organization: Beijing Institute of Heart, Lung and Blood Vessel Disease – sequence: 5 givenname: Yueping surname: Li fullname: Li, Yueping organization: Beijing Institute of Heart, Lung and Blood Vessel Disease – sequence: 6 givenname: Fei surname: Gao fullname: Gao, Fei organization: Beijing Institute of Heart, Lung and Blood Vessel Disease – sequence: 7 givenname: Yuyang surname: Liu fullname: Liu, Yuyang organization: Beijing Institute of Heart, Lung and Blood Vessel Disease – sequence: 8 givenname: Xiaoteng surname: Ma fullname: Ma, Xiaoteng organization: Beijing Institute of Heart, Lung and Blood Vessel Disease – sequence: 9 givenname: Yujie surname: Zhou fullname: Zhou, Yujie organization: Beijing Institute of Heart, Lung and Blood Vessel Disease |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35695557$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkttu1DAQhiNURLeFRwDlkpstPsSHCAlRVRwqVYILuLYcZ7x1ldiL7WzZp-CVcci2UC7gZiyNv_lnPP5PqiMfPFTVc4zOMJLoFRKSUdmiM4IIKUFSLvCjaoUpZ2uCODqqVjOznqHj6iSlG4QQERg9qY4p4y1jTKyqH59j2PiQsjP1Tg8T1MHWaZ8yjCXjvB30OOoc4r6OkLbBJyjZHr6XWG91duBzqm9dvq61mTLUJsTgdcHT3vcxjFBPBY-b4Pym3kIskPYQpvSbdD5D3BUhF_zT6rHVQ4Jnh_O0-vr-3ZeLj-urTx8uL86v1obRJq8157LpGAUjpZBSMwa4pdJKogUG1HPbCIslNJZ3QCwFiXrTdh3HXa8paulpdbno9kHfqG10Y5lEBe3Ur0SIG6VjWcoAqsMUYY4Ea6BpLOq16UnH2g432hrRyqL1ZtHaTt0IvSkviXp4IPrwxrtrtQk71RLCBMFF4OVBIIZvE6SsRpcMDMOyKUW4YK1sRDujL_7sdd_k7kcLwBbAxJBSBHuPYKRm56g756jZOergnFL3-q8647Kev6SM7Ib_Vr9dqotjQhz1bYhDr7LeDyHaqL1xSdF_S_wEshrh6g |
CitedBy_id | crossref_primary_10_1016_j_ajem_2025_02_025 crossref_primary_10_3233_JAD_230886 crossref_primary_10_3390_jpm13091408 crossref_primary_10_3390_ijms23179553 crossref_primary_10_3389_fcvm_2023_1284491 crossref_primary_10_3389_fendo_2023_1100453 crossref_primary_10_3390_jcm13206059 crossref_primary_10_1186_s12872_024_03763_9 crossref_primary_10_4103_bc_bc_32_24 crossref_primary_10_1016_j_isci_2023_108060 crossref_primary_10_1016_j_puhe_2022_10_005 crossref_primary_10_2147_JIR_S454117 crossref_primary_10_3390_jcm13051256 crossref_primary_10_1177_00033197241285970 crossref_primary_10_3390_biomedicines12051066 crossref_primary_10_31083_j_rcm2405153 crossref_primary_10_3389_fcvm_2024_1361088 crossref_primary_10_15829_1560_4071_20245823 crossref_primary_10_3389_fcvm_2024_1418781 crossref_primary_10_3389_fcvm_2022_1066219 crossref_primary_10_4103_tjem_tjem_198_23 crossref_primary_10_2147_JIR_S498292 crossref_primary_10_3390_cancers17060990 crossref_primary_10_1080_07853890_2023_2196438 crossref_primary_10_1186_s13098_024_01419_4 crossref_primary_10_2147_JIR_S421491 crossref_primary_10_1186_s12933_022_01627_0 crossref_primary_10_2147_JIR_S505797 crossref_primary_10_1016_j_heliyon_2024_e39029 crossref_primary_10_1080_07853890_2022_2104919 crossref_primary_10_1080_0886022X_2024_2330621 crossref_primary_10_1177_00033197231151564 crossref_primary_10_1186_s12872_022_02989_9 crossref_primary_10_1097_MD_0000000000036512 crossref_primary_10_1177_10815589241283739 crossref_primary_10_3389_fmed_2024_1404152 crossref_primary_10_3390_life13061395 crossref_primary_10_3390_jcdd12020079 crossref_primary_10_3389_fnut_2025_1540933 crossref_primary_10_1038_s41598_024_84759_5 crossref_primary_10_2147_JIR_S421021 crossref_primary_10_1186_s12872_024_04417_6 crossref_primary_10_2147_JIR_S432506 crossref_primary_10_3389_fimmu_2024_1324890 crossref_primary_10_1186_s12872_023_03403_8 crossref_primary_10_1002_iid3_70180 crossref_primary_10_1177_10760296231198042 crossref_primary_10_1186_s13578_024_01226_4 crossref_primary_10_2147_JIR_S435398 crossref_primary_10_7759_cureus_49391 crossref_primary_10_1111_eci_14332 crossref_primary_10_1177_00033197231158937 crossref_primary_10_1007_s00277_023_05518_6 crossref_primary_10_2147_JIR_S479253 crossref_primary_10_3390_jcdd10050199 crossref_primary_10_2174_011871529X269740231102045028 crossref_primary_10_31083_j_rcm2506202 crossref_primary_10_1016_j_toxicon_2023_107269 crossref_primary_10_1080_00015385_2023_2218020 crossref_primary_10_31083_j_rcm2312400 crossref_primary_10_2478_jce_2024_0014 crossref_primary_10_1002_iid3_1369 crossref_primary_10_1177_00033197231198678 |
Cites_doi | 10.3389/fcvm.2021.755806 10.1016/j.amjcard.2017.06.020 10.1160/TH11-02-0096 10.3109/00365513.2013.860619 10.1056/NEJMra043430 10.1007/s00380-010-0010-7 10.1161/CIRCULATIONAHA.104.504159 10.1093/cvr/cvy130 10.1016/0002-8703(92)90942-O 10.1016/S0140-6736(17)32154-2 10.1371/journal.pone.0007947 10.1097/FJC.0b013e31829f716a 10.1067/mhj.2001.115792 10.1177/0003319713479154 10.1007/s00270-021-02965-4 10.1161/CIRCRESAHA.114.302699 10.1016/j.jacc.2009.04.021 10.1016/j.intimp.2018.10.002 10.1007/s10753-011-9384-7 10.1093/eurheartj/ehm004 10.1093/eurheartj/ehab221 10.1038/s41598-021-97678-6 10.1056/NEJMoa1809798 10.1016/j.atherosclerosis.2016.04.015 10.1007/s00395-016-0535-8 10.1097/MD.0000000000012813 10.2217/bmm-2017-0235 10.1038/s41569-019-0169-2 10.1177/0003319713497992 10.1089/dia.2013.0097 10.2147/JIR.S283835 10.1136/heart.89.10.1200 10.1002/clc.23749 10.1177/1076029621999717 10.2174/1381612824666180116100310 10.1002/cncr.30057 10.1016/j.ehj.2004.05.002 10.2174/138161207780487593 10.1159/000068448 10.1007/s13311-016-0483-x 10.1242/jcs.114.1.131 10.2147/CIA.S339221 10.1016/0002-9149(84)90624-6 10.1056/NEJMoa1707914 10.1007/s10067-022-06122-1 10.1186/s12872-017-0507-4 10.1007/s10157-012-0728-x 10.1161/ATVBAHA.110.209296 10.1016/S0002-9149(96)00878-8 10.1016/j.jacc.2020.08.011 10.1073/pnas.85.20.7462 10.1093/eurheartj/ehaa1034 10.1080/00325481.2020.1809870 10.3109/10641963.2012.758734 |
ContentType | Journal Article |
Copyright | 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s) |
Copyright_xml | – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 – notice: 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2022 The Author(s) |
DBID | 0YH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1080/07853890.2022.2083671 |
DatabaseName | Taylor & Francis Open Access (WRLC) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | K. Han et al |
EISSN | 1365-2060 |
EndPage | 1677 |
ExternalDocumentID | oai_doaj_org_article_b130160754e44f0dacd2b59b14afc798 PMC9225721 35695557 10_1080_07853890_2022_2083671 2083671 |
Genre | Research Article Journal Article |
GroupedDBID | --- 00X 03L 0YH 23M 36B 4.4 5GY 5RE AALUX ABLKL ABUPF ACENM ACGEJ ACGFS ADCVX ADRBQ ADXPE AENEX AEOZL AFKVX AGYJP AIJEM AJWEG ALMA_UNASSIGNED_HOLDINGS BABNJ BLEHA BOHLJ CCCUG CS3 DKSSO EBD EBS EMB EMOBN F5P GROUPED_DOAJ H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- OK1 P2P RPM SV3 TDBHL TFDNU TFL TFW V1S WH7 ~1N AAFWJ AAYXX CITATION .55 .GJ 34G 39C 3O- 53G 5VS AALIY AAORF AAPXX ABWCV ABZEW ADFZZ AFFNX AFLEI AJVHN AWYRJ BRMBE CAG CGR COF CUY CVF CYYVM CZDIS DRXRE DWTOO ECM EIF EJD JENTW M44 NPM NUSFT OVD QQXMO TEORI X7M ZGI ZXP 7X8 5PM |
ID | FETCH-LOGICAL-c534t-a6684b53ec88788a55e1938f82a71e0d6f47f18e4f6be2f3e80dc9bb61bda3093 |
IEDL.DBID | DOA |
ISSN | 0785-3890 1365-2060 |
IngestDate | Wed Aug 27 01:12:08 EDT 2025 Thu Aug 21 14:11:54 EDT 2025 Thu Jul 10 19:29:19 EDT 2025 Thu Apr 03 07:04:27 EDT 2025 Tue Aug 05 12:07:51 EDT 2025 Thu Apr 24 22:53:10 EDT 2025 Wed Dec 25 09:05:38 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | percutaneous coronary intervention acute coronary syndrome cardiovascular outcomes Systemic inflammatory response index |
Language | English |
License | open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c534t-a6684b53ec88788a55e1938f82a71e0d6f47f18e4f6be2f3e80dc9bb61bda3093 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Supplemental data for this article is available online at https://doi.org/10.1080/07853890.2022.2083671. |
OpenAccessLink | https://doaj.org/article/b130160754e44f0dacd2b59b14afc798 |
PMID | 35695557 |
PQID | 2675984791 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_b130160754e44f0dacd2b59b14afc798 crossref_primary_10_1080_07853890_2022_2083671 pubmed_primary_35695557 informaworld_taylorfrancis_310_1080_07853890_2022_2083671 proquest_miscellaneous_2675984791 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9225721 crossref_citationtrail_10_1080_07853890_2022_2083671 |
PublicationCentury | 2000 |
PublicationDate | 2022-12-31 |
PublicationDateYYYYMMDD | 2022-12-31 |
PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-31 day: 31 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Annals of medicine (Helsinki) |
PublicationTitleAlternate | Ann Med |
PublicationYear | 2022 |
Publisher | Taylor & Francis Taylor & Francis Group |
Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
References | e_1_3_5_29_1 e_1_3_5_27_1 e_1_3_5_25_1 e_1_3_5_23_1 e_1_3_5_44_1 e_1_3_5_46_1 e_1_3_5_48_1 e_1_3_5_3_1 e_1_3_5_40_1 e_1_3_5_42_1 e_1_3_5_9_1 e_1_3_5_21_1 e_1_3_5_5_1 e_1_3_5_7_1 e_1_3_5_18_1 e_1_3_5_39_1 e_1_3_5_16_1 e_1_3_5_37_1 e_1_3_5_14_1 e_1_3_5_35_1 e_1_3_5_12_1 e_1_3_5_33_1 e_1_3_5_50_1 e_1_3_5_52_1 e_1_3_5_54_1 e_1_3_5_10_1 e_1_3_5_31_1 e_1_3_5_28_1 e_1_3_5_26_1 e_1_3_5_24_1 e_1_3_5_22_1 e_1_3_5_45_1 e_1_3_5_47_1 e_1_3_5_49_1 e_1_3_5_2_1 e_1_3_5_41_1 e_1_3_5_43_1 e_1_3_5_8_1 e_1_3_5_20_1 e_1_3_5_4_1 e_1_3_5_6_1 e_1_3_5_17_1 e_1_3_5_38_1 e_1_3_5_15_1 e_1_3_5_13_1 e_1_3_5_36_1 e_1_3_5_11_1 e_1_3_5_34_1 e_1_3_5_55_1 e_1_3_5_19_1 e_1_3_5_51_1 e_1_3_5_53_1 e_1_3_5_32_1 e_1_3_5_30_1 |
References_xml | – ident: e_1_3_5_15_1 doi: 10.3389/fcvm.2021.755806 – ident: e_1_3_5_33_1 doi: 10.1016/j.amjcard.2017.06.020 – ident: e_1_3_5_27_1 doi: 10.1160/TH11-02-0096 – ident: e_1_3_5_40_1 doi: 10.3109/00365513.2013.860619 – ident: e_1_3_5_5_1 doi: 10.1056/NEJMra043430 – ident: e_1_3_5_30_1 doi: 10.1007/s00380-010-0010-7 – ident: e_1_3_5_9_1 doi: 10.1161/CIRCULATIONAHA.104.504159 – ident: e_1_3_5_28_1 doi: 10.1093/cvr/cvy130 – ident: e_1_3_5_6_1 doi: 10.1016/0002-8703(92)90942-O – ident: e_1_3_5_2_1 doi: 10.1016/S0140-6736(17)32154-2 – ident: e_1_3_5_54_1 doi: 10.1371/journal.pone.0007947 – ident: e_1_3_5_45_1 doi: 10.1097/FJC.0b013e31829f716a – ident: e_1_3_5_32_1 doi: 10.1067/mhj.2001.115792 – ident: e_1_3_5_47_1 doi: 10.1177/0003319713479154 – ident: e_1_3_5_38_1 doi: 10.1007/s00270-021-02965-4 – ident: e_1_3_5_8_1 doi: 10.1161/CIRCRESAHA.114.302699 – ident: e_1_3_5_24_1 doi: 10.1016/j.jacc.2009.04.021 – ident: e_1_3_5_37_1 doi: 10.1016/j.intimp.2018.10.002 – ident: e_1_3_5_3_1 doi: 10.1007/s10753-011-9384-7 – ident: e_1_3_5_53_1 doi: 10.1093/eurheartj/ehm004 – ident: e_1_3_5_50_1 doi: 10.1093/eurheartj/ehab221 – ident: e_1_3_5_34_1 doi: 10.1038/s41598-021-97678-6 – ident: e_1_3_5_52_1 doi: 10.1056/NEJMoa1809798 – ident: e_1_3_5_12_1 doi: 10.1016/j.atherosclerosis.2016.04.015 – ident: e_1_3_5_25_1 doi: 10.1007/s00395-016-0535-8 – ident: e_1_3_5_35_1 doi: 10.1097/MD.0000000000012813 – ident: e_1_3_5_44_1 doi: 10.2217/bmm-2017-0235 – ident: e_1_3_5_4_1 doi: 10.1038/s41569-019-0169-2 – ident: e_1_3_5_39_1 doi: 10.1177/0003319713497992 – ident: e_1_3_5_41_1 doi: 10.1089/dia.2013.0097 – ident: e_1_3_5_20_1 doi: 10.2147/JIR.S283835 – ident: e_1_3_5_7_1 doi: 10.1136/heart.89.10.1200 – ident: e_1_3_5_55_1 doi: 10.1002/clc.23749 – ident: e_1_3_5_14_1 doi: 10.1177/1076029621999717 – ident: e_1_3_5_51_1 doi: 10.2174/1381612824666180116100310 – ident: e_1_3_5_17_1 doi: 10.1002/cncr.30057 – ident: e_1_3_5_10_1 doi: 10.1016/j.ehj.2004.05.002 – ident: e_1_3_5_21_1 doi: 10.2174/138161207780487593 – ident: e_1_3_5_31_1 doi: 10.1159/000068448 – ident: e_1_3_5_11_1 doi: 10.1007/s13311-016-0483-x – ident: e_1_3_5_22_1 doi: 10.1242/jcs.114.1.131 – ident: e_1_3_5_18_1 doi: 10.2147/CIA.S339221 – ident: e_1_3_5_26_1 doi: 10.1016/0002-9149(84)90624-6 – ident: e_1_3_5_49_1 doi: 10.1056/NEJMoa1707914 – ident: e_1_3_5_19_1 doi: 10.1007/s10067-022-06122-1 – ident: e_1_3_5_43_1 doi: 10.1186/s12872-017-0507-4 – ident: e_1_3_5_42_1 doi: 10.1007/s10157-012-0728-x – ident: e_1_3_5_29_1 doi: 10.1161/ATVBAHA.110.209296 – ident: e_1_3_5_36_1 doi: 10.1016/S0002-9149(96)00878-8 – ident: e_1_3_5_48_1 doi: 10.1016/j.jacc.2020.08.011 – ident: e_1_3_5_23_1 doi: 10.1073/pnas.85.20.7462 – ident: e_1_3_5_13_1 doi: 10.1093/eurheartj/ehaa1034 – ident: e_1_3_5_16_1 doi: 10.1080/00325481.2020.1809870 – ident: e_1_3_5_46_1 doi: 10.3109/10641963.2012.758734 |
SSID | ssj0002710 |
Score | 2.6104345 |
Snippet | The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.
The aim of this study was to examine the association... The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.BACKGROUNDThe systemic inflammatory response index (SIRI) is... Background The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases.Objectives The aim of this study was to examine... |
SourceID | doaj pubmedcentral proquest pubmed crossref informaworld |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1667 |
SubjectTerms | acute coronary syndrome Acute Coronary Syndrome - complications Cardiology & Cardiovascular Disorders cardiovascular outcomes Humans percutaneous coronary intervention Percutaneous Coronary Intervention - adverse effects Percutaneous Coronary Intervention - methods Prognosis Risk Assessment Risk Factors Systemic inflammatory response index Systemic Inflammatory Response Syndrome - epidemiology Systemic Inflammatory Response Syndrome - etiology Treatment Outcome |
SummonAdditionalLinks | – databaseName: Taylor & Francis Open Access (WRLC) dbid: 0YH link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LixQxEA6ygngR344vInht7UeSTo4qLoOw4sEFPYU81wXtXnp6fsf-ZauS9DizKHvwMjDdVdMZ6qtUpVP1hZDXAnADeYGrGul4xVpvKoWVAAJpAjrTd4Jjv_PJZ7E-ZZ--8aWacFPKKnENHTNRRJqr0bmN3SwVcW8hqoGbqhpWdy32UslOYBf5zRbRCpCuv693k3HbJ0ICVKlQZ2ni-dfPHISnxOJ_hcP0b5no1YLKvQh1fJfcKaklfZexcI_cCMN9cuukbJ4_IJdfphHL6uA2RY7vQMdIM5MzXIGnAzh-pU13OuXK2UATmSJ80sK_uqH44pYat50Ddch-YEB8oT2g2JE2nY0QDulFmEDIDGHcbv5Inu-VWD4kp8cfv35YV-U8hsrxjs2VEUIyy7vgYGaS0nAewMwyytb0Tai9iKyPjQwsChva2AVZe6esFY31BndcH5GjYRzCE0J9dEZFaa2vJTNeqVbaRjiOypDj-BVhixm0K2TleGbGT90snKbFehqtp4v1VuTNTu0is3Vcp_AebbwTRrLtdGGcznTxXW0hziMPH2eBsVh743xrubINM9H1Sq6I2keIntO7lpgPRtHdNQN4tcBJg2Pjbk22jG5hKacgd1Ag8zjDazfMjgvFOe9XpD8A3sH_OLwznP9I5OEKJnBY9T_9jzE_I7fxa6a7fE6O5mkbXkBqNtuXyfl-A5wdMYY priority: 102 providerName: Taylor & Francis |
Title | Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention |
URI | https://www.tandfonline.com/doi/abs/10.1080/07853890.2022.2083671 https://www.ncbi.nlm.nih.gov/pubmed/35695557 https://www.proquest.com/docview/2675984791 https://pubmed.ncbi.nlm.nih.gov/PMC9225721 https://doaj.org/article/b130160754e44f0dacd2b59b14afc798 |
Volume | 54 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1Lb9QwEIAt6AFxQbxZHisjcQ3kYTv2sa1arSq14kClcrL8hEqQVGn2d_QvM2Mny26FtBcuOThjJc5MPGN7_JmQTwLsBuICV1TS8YLV3hQKMwEEYgIa0zaC437n8wuxumRnV_xq66gvzAnLeOD84b5Y6GQRgsZZYCyW3jhfW65sxUx0rUrbfMHnzYOpqQ-u28QhAP_HC3DJ5bx3B6naUIZFMDascSeWbERb7XilBO-_hy79VwB6P49yyzGdPiVPpoiSHuaWPCMPQvecPDqf1sxfkLuvQ4_ZdHCbIto70D7SDHCGEng62MTvtNZOh5wwG2hiKMKVTtjVW4rztdS49RioQ-iBAfGZdkBxI9rwowcvSG_CAEKmC_369q_k9VZm5UtyeXry7XhVTMcwFI43bCyMEJJZ3gQHHZKUhvMA2pVR1qatQulFZG2sZGBR2FDHJsjSO2WtqKw3uND6ihx0fRfeEOqjMypKa30pmfFK1dJWwnGsDKGNXxA2q0G7iVGOR2X80tWMMp20p1F7etLegnzeVLvJkI59FY5QxxthZGynArA8PVme3md5C6K2LUSPaYol5vNQdLPnBT7O5qThf8ZFmqwZXcMITkHIoEDmdTavzWs2XCjOebsg7Y7h7bRj9053_TMxwxX02zDYf_s_Gv6OPMa2ZNzle3IwDuvwAUKz0S7Jw_L7apn-xWWaOfsDC-A2rg |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQkYAL4s3yNBLXQB62Yx8BUS3QrTi0UjlZfpZKkFRp9nfwl5mxk2W3AvXAJQd7JnE0M56xPfOZkNcC9AbiAldU0vGC1d4UCjMBBMIENKZtBMd659WhWB6zzyf8ZKsWBtMqcQ0dM1BEmqvRuHEzek6JewtuDexUlbC8q7GYSjYCy8ivc3C-eH1D-W25mY3rNiESIEuBPHMVz79es-OfEoz_JRDTv4WilzMqt1zU_h1ye4ot6busDHfJtdDdIzdW0-n5ffLr69BjXh10UwT5DrSPNEM5Qwt8HbTjZzp1p0NOnQ00oSnCk04ArBcUd26pcesxUIfwBwbIZ9wDiiVpw2kP_pCehwGITBf69cUfyrOtHMsH5Hj_49GHZTFdyFA43rCxMEJIZnkTHExNUhrOA8hZRlmbtgqlF5G1sZKBRWFDHZsgS--UtaKy3uCR60Oy1_VdeEyoj86oKK31pWTGK1VLWwnHkRmCHL8gbBaDdhNaOV6a8UNXM6jpJD2N0tOT9BbkzYbtPMN1XMXwHmW8IUa07dTQD6d6Ml5twdEjEB9ngbFYeuN8bbmyFTPRtUouiNrWED2mzZaYb0bRzRUDeDWrkwbLxuOaLBldw1pOQfCggOZRVq_NMBsuFOe8XZB2R_F2_mO3pzv7ntDDFczgsOx_8h9jfkluLo9WB_rg0-GXp-QWdmXsy2dkbxzW4TnEaaN9kQzxNyekNPo |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQK1VcEOW5UMBIXAN52I59pMBqebTqgUpwsvxsK0GyymZ_B3-ZGSdZditQD1xysGcSRzPjGdsznwl5JUBvIC5wWSEdz1jpTaYwE0AgTEBl6kpwrHc-ORWLc_bpG5-yCVdjWiWuoeMAFJHmajTupY9TRtwb8GpgpiqH1V2JtVSyElhFvs8l-HpQ6fz7YjMZl3UCJECWDHmmIp5_vWbHPSUU_2sYpn-LRK8nVG55qPldcmcMLenbQRcOya3Q3CMHJ-Ph-X3y66xrMa0OuilifAfaRjogOUMLfB2U42c6dKfdkDkbaAJThCcd8VdXFDduqXHrPlCH6AcGyCfYA4oVad1FC-6QLkMHRKYJ7Xr1h_JqK8XyATmff_j6bpGN9zFkjlesz4wQklleBQczk5SG8wBillGWpi5C7kVkdSxkYFHYUMYqyNw7Za0orDd44vqQ7DVtEx4T6qMzKkprfS6Z8UqV0hbCcWSGGMfPCJvEoN0IVo53ZvzQxYRpOkpPo_T0KL0Zeb1hWw5oHTcxHKOMN8QItp0a2u5Cj7arLfh5xOHjLDAWc2-cLy1XtmAmulrJGVHbGqL7tNcSh4tRdHXDAF5O6qTBsPG0ZpCMLmEppyB2UEDzaFCvzTArLhTnvJ6Rekfxdv5jt6e5ukzg4QomcFj1P_mPMb8gB2fv5_rLx9PPT8lt7BmQL4_IXt-twzOI0nr7PNnhbyxQNCw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+systemic+inflammatory+response+index+in+patients+with+acute+coronary+syndrome+undergoing+percutaneous+coronary+intervention&rft.jtitle=Annals+of+medicine+%28Helsinki%29&rft.au=Han%2C+Kangning&rft.au=Shi%2C+Dongmei&rft.au=Yang%2C+Lixia&rft.au=Wang%2C+Zhijian&rft.date=2022-12-31&rft.eissn=1365-2060&rft.volume=54&rft.issue=1&rft.spage=1667&rft_id=info:doi/10.1080%2F07853890.2022.2083671&rft_id=info%3Apmid%2F35695557&rft.externalDocID=35695557 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0785-3890&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0785-3890&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0785-3890&client=summon |